Skip to main content

Table 1 Patients’ characteristics

From: Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

Description Total (N = 16)
Demographic characteristics
 Age, median (Range) 67.5 (51, 91)
 Sex, n (%)
  Female 8 (50.0%)
 Living status, n (%)
  Living with husband/wife/partner 12 (75.0%)
  Living alone 3 (18.7%)
  Living with parents/family or friends 1 (6.3%)
 Work status, n (%)
  Retired 13 (81.3%)
  Not working due to MDS 2 (12.5%)
  Disability 1 (6.3%)
 Race, n (%)
  Caucasian 15 (93.7%)
  Black/African American 1 (6.3%)
 Highest level of education, n (%)
  College or university 7 (43.8%)
  Some years of college 5 (31.3%)
  Graduation or professional degree 2 (12.5%)
  Some high school 1 (6.3%)
  High school diploma or general educational development 1 (6.3%)
Clinical characteristics
 Years since diagnosis, Median (Range) 3.6 (0.25, 50.8)
 IPSS risk category, n (%)  
  Intermediate-1-risk 9 (56.2)
  Low-risk 7 (43.8)
 MDS Subtypea, n (%)
  Refractory Anemia with Ring Sideroblasts (RARS) 7 (43.8)
  Refractory Cytopenia with Multilineage Dysplasia (RCMD) 6 (37.5)
  MDS Unclassified (MDS-U) 2 (12.5)
  Refractory Cytopenia with Unilineage Dysplasia (RCUD) 1 (6.3)
  MDS associated with del(5q) including the 5q- syndrome 1 (6.3)
 ECOG performance status, n (%)
  0 7 (43.8)
  1 9 (56.2)
 Chronic diseases other than MDS, n (%) 8 (50.0)
  Cardiovascular 6 (75.0)
  Endocrinological/Nutritional 3 (37.5)
  Rheumatological 2 (25.0)
  Gastroenterological 1 (12.5)
  Hematological 1 (12.5)
  Gynecological 1 (12.5)
  Dermatological 1 (12.5)
 Current prescribed pharmacological treatment n (%)
  Erythropoietin 3 (18.8)
  Deferasirox 3 (18.8)
  Decitabine 2 (12.5)
  Deferoxamine 2 (12.5)
  Azacitidine 2 (12.5)
  Granulocyte-colony stimulating factor 1 (6.3)
  Prednisone 1 (6.3)
  Rituximab 1 (6.3)
  Coenzyme Q10 1 (6.3)
  Furosemide 1 (6.3)
 Previous pharmacological treatment n (%)
  Erythropoietin 10 (62.5)
  Lenalidomide 4 (25.0)
  Azacitidine 2 (12.5)
  Filgrastim 2 (12.5)
  Hypomethylating agents 1 (6.3)
  Granulocyte-colony stimulating factor 1 (6.3)
  Deferasirox 1 (6.3)
  Danazol 1 (6.3)
  1. aTotal n is greater than sample size due to an error in reporting in which one participant was reported to have two types of MDS: RCMD and del(5q)
  2. IPSS International Prognostic Scoring System, MDS Myelodysplastic syndrome